Publications, Pharmaceutical

Confirming bioequivalence for a generic tiotropium dry powder inhalers

Pharmacokinetic (PK) profiling is a central strategy for the demonstration of bioequivalence in generic dry powder inhaler development.

This paper describes a study in which in vitro testing under clinically relevant conditions, an in silico regional deposition model and a physiologically-based PK simulation model were used together to compare Test and Reference tiotropium products. In vitro testing detected significant batch to batch variability in the Reference product while in silico and PK data, in combination, highlighted the potential for variability in peripheral dose deposition to impact PK profile. The developed in silico model, once validated, has considerable potential to elucidate correlations between in vitro and in vivo data and help generic developers to establish and demonstrate robust bioequivalence.

Download Publication
25 Jun 2020

Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery

Find Out More

This Might Also Be of Interest

12 Jul 2022

Digital Health and Digital Therapeutics: Where are we heading and...

Webinars, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
12 Jul 2022

How pMDIs are transforming Asthma and COPD treatments

Publications, Pharmaceutical, Market Insights, Product Solutions, Sustainability, Device Innovations

Read More
5 Jul 2022

Drug, Device, Digital: Reimagined Healthcare

Webinars, Pharmaceutical, Innovation & Insights, Brand Differentiation, Market Insights, Product Solutions

Read More
30 Jun 2022

Supporting Patients and HCPs with New Digital Technology

Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
1 2 3 14
Back To Top